Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 save search
IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma
Published: 2022-05-18 (Crawled : 12:20) - biospace.com/
IOBT | $1.47 0.0% 92K
|
|
| O: -2.9%
H: 3.0%
C: -17.91%
io102 keytruda treatment melanoma biotech trial phase 3
Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification
Published: 2022-05-17 (Crawled : 18:00) - biospace.com/
KMDA | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 1.68%
H: 3.0%
C: 2.07%
expansion six trial positive phase 3
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
ETTX | $2.19 -0.46% 0.46%
|
Health Technology
|
| O: 1.71%
H: 1.69%
C: -0.56%
conference trial therapeutics phase 3
aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
Published: 2022-05-16 (Crawled : 19:00) - biospace.com/
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: 0.0%
H: 5.23%
C: 0.65%
atyr1923 pharma phase 3
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
Published: 2022-05-12 (Crawled : 19:00) - biospace.com/
SRRA | $54.99 0.04% 0.0%
|
Health Technology
|
| O: -0.06%
H: 0.15%
C: 0.13%
presentation phase 3
Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease
Published: 2022-05-11 (Crawled : 13:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
rinvoq disease response one phase 3
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 20.75%
H: 0.0%
C: 0.0%
covid-19 fda sabizabulin authorization positive phase 3 emergency use authorization
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Published: 2022-05-10 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: -7.98%
H: 3.06%
C: 1.02%
ongoing positive phase 3
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome PatientsPhase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022
Published: 2022-05-09 (Crawled : 13:00) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -2.83%
H: 0.97%
C: -9.22%
fda expected trial therapeutics phase 3
Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally
Published: 2022-05-06 (Crawled : 14:00) - prnewswire.com
CTXR | $0.7477 -7.18% -7.73% 1.7M
|
Health Technology
|
| O: 3.78%
H: 13.37%
C: 2.97%
trial phase 3
Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial
Published: 2022-05-06 (Crawled : 13:00) - prnewswire.com
EVFM | $0.0141 -16.94% 180K
|
Health Technology
|
| O: 876.43%
H: 0.0%
C: 0.0%
women phexxi infections trial phase 3
Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA™) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting
Published: 2022-05-06 (Crawled : 01:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -7.06%
H: 0.63%
C: -3.8%
sp-102 presentation phase 3
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
Published: 2022-05-05 (Crawled : 19:00) - biospace.com/
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: -1.04%
H: 0.77%
C: -0.67%
program phase 3
Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
Published: 2022-05-05 (Crawled : 16:00) - globenewswire.com
ZLAB | News | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: -1.73%
H: 0.38%
C: -3.24%
ARGX | $360.11 0.47% 0.47% 330K
|
Health Technology
|
| O: 3.33%
H: 6.9%
C: 4.68%
vyvgart trial positive phase 3
Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
PALI | $4.735 -6.61% -7.07% 140K
|
Manufacturing
|
| O: -2.21%
H: 7.35%
C: 4.49%
lb1148 clearance trial china phase 3
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus
Published: 2022-05-05 (Crawled : 12:20) - biospace.com/
MRNS | $1.38 -2.13% -2.17% 2.6M
|
Health Technology
|
| O: -2.66%
H: 1.29%
C: -2.42%
epilepticus trial phase 3
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
ARGX | $360.11 0.47% 0.47% 330K
|
Health Technology
|
| O: 3.33%
H: 6.9%
C: 4.68%
vyvgart trial positive phase 3
SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Published: 2022-05-04 (Crawled : 13:00) - biospace.com/
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 2.26%
H: 0.0%
C: -4.04%
ongoing phase 3
Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1
Published: 2022-05-03 (Crawled : 12:20) - prnewswire.com
ORMP | $2.265 2.96% 2.87% 110K
|
Health Technology
|
| O: 6.4%
H: 4.69%
C: 0.88%
insulin enroll phase 3
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Published: 2022-05-03 (Crawled : 12:20) - biospace.com/
BTAI | $2.77 8.63% 7.94% 620K
|
Health Technology
|
| O: 4.1%
H: 1.65%
C: 1.01%
treatment disease trial therapeutics alzheimer’s phase 3 alzheimer's
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.